Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Video Interview: Placental Stem Therapy Offers 'Off The Shelf' Promise

This article was originally published in Scrip

Executive Summary

Pluristem Therapeutics chair and CEO Zami Aberman explains to Mike Ward, global director of content for Informa Pharma Insights how stem cell therapy will shape the industry. Using placental cells and a proprietary, three-dimensional (3D) technology platform, Pluristem is developing "off the shelf" cell therapies for a broad spectrum of diseases. Pluristem converts human placental stem cells into PLacental eXpanded (PLX) cells, which secrete therapeutic proteins in response to signals produced by damaged tissues. The company's pipeline targets multiple indications involving inflammation and ischemia, including peripheral artery disease, muscle injury, preeclampsia, and graft versus host disease. Aberman tells Mike Ward that his company intends to use the $17m it raised in 2015 to complete current clinical studies and start new ones.

Advertisement

Related Content

India Clears Off-The-Shelf Stem Cell Therapy for Buerger's

Topics

Advertisement
UsernamePublicRestriction

Register

SC064767

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel